Diacerein has a weak effect on the catabolic pathway of human osteoarthritis synovial fibroblast - Comparison to its effects on osteoarthritic chondrocytes

Rheumatology

Volumn 47, Issue 5, 2008, Pages 627-633

  Alvarez Soria M A ^a   Herrero Beaumont, G ^a   Sanchez Pernaute O ^a   Bellido, M ^a   Largo, R ^a  

^a Hospital UniversitarioFundación Jiménez Díaz   (Spain)

Author keywords

Cytokines and inflammatory mediators; Extracellular matrix; Non steroidal anti inflammatory drugs; Osteoarthritis; Synovium

Indexed keywords

AUTACOID; CELECOXIB; COLLAGENASE 3; CYCLOOXYGENASE 2; DIACETYLRHEIN; DICLOFENAC; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDOMETACIN; INTERLEUKIN 1BETA; INTERSTITIAL COLLAGENASE; MELOXICAM; NITRITE; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN E2;

ARTICLE; CARTILAGE CELL; CATABOLISM; CELL STIMULATION; CELL TYPE; CELL VIABILITY; CONTROLLED STUDY; FIBROBLAST; GEL MOBILITY SHIFT ASSAY; HUMAN; HUMAN CELL; INHIBITION KINETICS; JOINT PROSTHESIS; OSTEOARTHRITIS; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PROTEIN EXPRESSION; PROTEIN MODIFICATION; SYNOVIOCYTE; SYNOVIUM; WESTERN BLOTTING;

ANTHRAQUINONES; ANTI-INFLAMMATORY AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CARTILAGE, ARTICULAR; CELLS, CULTURED; CHONDROCYTES; CYCLOOXYGENASE 2; DINOPROSTONE; FIBROBLASTS; HUMANS; INTERLEUKIN-1BETA; KNEE JOINT; MATRIX METALLOPROTEINASE 1; MATRIX METALLOPROTEINASE 13; NF-KAPPA B; NITRITES; OSTEOARTHRITIS, KNEE; STATISTICS, NONPARAMETRIC; STIMULATION, CHEMICAL; SYNOVIAL MEMBRANE;

EID: 42949092586     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ken116     Document Type: Article

References (51)

1. Pelletier JP, Martel-Pelletier J, Howell DS. Etiopatogenesis of osteoarthritis. Baltimore: Lippincott Williams and Wilkins, 2001;1969-84.
2. Farahat MN, Yanni G, Poston R, Panayi GS. Cytokine expression in synovial membranes of patients with rheumatoid arthritis and osteoarthritis. Ann Rheum Dis 1993;52:870-5.
3. Benito MJ, Veale DJ, FitzGerald O, Van den Berg WB, Bresnihan B. Synovial tissue inflammation in early and late osteoarthritis. Ann Rheum Dis 2005;64:1263-7.
4. Alvarez-Soria MA, Largo R, Santillana J et al. Long term NSAID treatment inhibits COX-2 synthesis in the knee synovial membrane of patients with osteoarthritis. Differential pro-inflammatory cytokine profile between celecoxib and aceclofenac. Ann Rheum Dis 2006;65:998-1005.
5. Konttinen YT, Li TF, Hukkanen M, Ma J, Xu JW, Virtanen I. Fibroblast biology. Signals targeting the synovial fibroblast in arthritis. Arthritis Res 2000;2:348-55.
6. Vincenti MP, Brinckerhoff CE. Early response genes induced in chondrocytes stimulated with the inflammatory cytokine interleukin-1 beta. Arthritis Res 2001;3:381-8.
7. Hardy MM, Seibert K, Manning PT et al. Cyclooxygenase 2-dependent prostaglandin E2 modulates cartilage proteoglycan degradation in human osteoarthritis explants. Arthritis Rheum 2002;46:1789-803.
8. Goldring MB, Berenbaum F. The regulation of chondrocyte function by proinflammatory mediators: Prostaglandins and nitric oxide. Clin Orthop Relat Res 2004;427:S37-46.
9. Berenbaum F. Signal transduction: Target in osteoarthritis. Curr Opin Rheumatol 2004;16:616-22.
10. Yaron M, Shirazi I, Yaron I. Anti-interleukin-1 effects of diacerein and rhein in human osteoarthritic synovial tissue and cartilage cultures. Osteoarthritis Cartilage 1999;7:272-80.
11. Tamura T, Shirai T, Kosaka N, Ohmori K, Takafumi N. Pharmacological studies of diacerein in animal models of inflammation, arthritis and bone resorption. Eur J Pharmacol 2002;448:81-7.
12. Pelletier JP, Mineau F, Fernandes JC, Duval N, Martel-Pelletier J. Diacerhein and rhein reduce the interleukin 1 beta stimulated inducible nitric oxide synthesis level and activity while stimulating cyclooxygenase-2 synthesis in human osteoarthritic chondrocytes. J Rheumatol 1998;25:2417-24.
13. Martin G, Bogdanowicz P, Domagala F, Ficheux H, Pujol JP. Rhein inhibits interleukin-1 beta-induced activation of MEK/ERK pathway and DNA binding of NFkappa B and AP1 in chondrocytes cultured in hypoxia: A potential mechanism for its disease-modifying effect in osteoarthritis. Inflammation 2003;27:233-46.
14. Fidelix TS, Soares BG, Trevisani VF. Diacerein for osteoarthritis. Cochrane Database Syst Rev 2006;25:CD005117. DOI: 10.1002/ 14651858.CD005117.pub2.
15. Dougados M, Nguyen M, Berdah L, Mazieres B, Vignon E, Lequesne M. ECHODIAH Investigators Study Group. Evaluation of the structure-modifying effects on diacerein in hip osteoarthritis: ECHODIAH, a three year, placebo controlled trial. Evaluation of the chondromodulating effect of diacerein in OA of the hip. Arthritis Rheum 2001;44:2539-47.
16. Pham T, Le Henanff A, Ravaud P, Dieppe P, Paolozzi L, Dougados M. Evaluation of the symptomatic and structural efficacy of a new hyaluronic acid compound, NRD101, in comparison with diacerein and placebo in a 1 year randomised controlled study in symptomatic knee osteoarthritis. Ann Rheum Dis 2004;63:1611-17.
17. Yoshida H, Nakamura M. Inhibition by angiotensin converting enzyme inhibitors of endothelin secretion from cultured human endothelial cells. Life Sci 1992; 50:PL195-200.
18. Wilkinson LS, Pitsillides AA, Wörrall JG, Edwards JCW. Light microscopic characterization of the fibroblast-like synovial intimal cell (synoviocyte). Arthritis Rheum 1992;35:1179-84.
19. Reginato AM, Lozzo RV, Jimenez SA. Formation of nodular structures resembling mature articular cartilage in long-term primary cultures of human fetal epiphyseal chondrocytes on a hydrogel substrate. Arthritis Rheum 1994;37:1338-49.
20. Nicolas P, Tod M, Padoin C, Petitjean O. Clinical pharmacokinetics of diacerein. Clin Pharmacokinet 1998;35:347-59.
21. Clemett D, Goa KL. Celecoxib: A review of its use in osteoarthritis, rheumatoid arthritis and acute pain. Drugs 2000;59:957-80.
22. Todd PA, Sorkin EM. Diclofenac sodium. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs 1988;35:244-85.
23. Turck D, Roth W, Busch U. A review of the clinical pharmacokinetics of meloxicam. Br J Rheumatol 1996;35:13-6.
24. Oberbauer R, Krivanek P, Tumheim K. Pharmacokinetics of indomethacin in the elderly. Clin Pharmacokinet 1993;24:428-34.
25. Largo R, Alvarez-Soria MA, Díez-Ortego I et al. Glucosamine inhibits IL-1beta- induced NFκB activation. Osteoarthritis Cartilage 2003;11:290-8.
26. Sanchez C, Mathy-Hartert M, Deberg MA, Ficheux H, Reginster JY, Henrotin YE. Effects of rhein on human articular chondrocytes in alginate beads. Biochem Pharmacol 2003;65:377-88.
27. Tak PP, Firestein GS. NFkappaB: A key role in inflammatory diseases. J Clin Invest 2001;107:7-11.
28. Mor A, Abramson SB, Pillinger MH. The fibroblast-like synovial cell in rheumatoid arthritis: A key player in inflammation and joint destruction. Clin Immunol 2005;115:118-28.
29. Nishimura M, Segami N, Kaneyama K, Suzuki T, Miyamaru M. Relationship between pain-related mediators and both synovitis and join pain in patients with internal derangements and osteoarthritis of the temporomandibular joint. Oral Surg Oral Med 2002;94:328-32.
30. Tamura T, Kosaka N, Ishiwa J, Sato T, Nagase H, Ito A. Rhein, an active metabolite of diacerein, down-regulates the production of pro-matrix metalloproteinases-1, -3, -9 and -13 and up-regulates the production of tissue inhibitor of metalloproteinase-1 in cultured rabbit articular chondrocytes. Osteoarthritis Cartilage 2001;9:257-63.
31. Guicheux J, Palmer G, Relic B et al. Primary human articular chondrocytes, dedifferentiated chondrocytes, and synoviocytes exhibit differential responsiveness to interleukin-4: Correlation with the expression pattern of the common receptor gamma chain. J Cell Physiol 2002;192:93-101.
32. Palombella VJ, Conner EM, Fuseler JW et al. Role of the proteasome and NFkappaB in streptococcal cell wall-induced polyarthritis. Proc Natl Acad Sci USA 1998; 95:15671-6.
33. Tanabe T, Tohnai N. Cyclooxygenase isozymes and their gene structures and expression. Prostaglandins Other Lipid Mediat 2002;68-69:95-114.
34. Inoue H, Taba Y, Miwa Y, Yokota C, Miyagi M, Sasaguri T. Transcriptional and posttranscriptional regulation of cyclooxygenase-2 expression by fluid shear stress in vascular endothelial cells. Arterioscler Thromb Vasc Biol 2002;22:1415-20.
35. Pharm H, Chong B, Vincenti R, Slice LW. Ang II and EGF synergistically induce COX-2 expression via CREB in intestinal epithelial cells. J Cell Physiol 2008; 214:96-109.
36. Verbruggen G. Chondroprotective drugs in degenerative joint diseases. Rheumatology 2006;45:129-38.
37. Takada Y, Bhardwaj A, Potdar P, Aggarwal BB. Nonsteroidal anti-infammatory agents differ in their ability to suppress NFκB activation, inhibition of expression of cyclooxygenase-2 and cyclin D1, and abrogation of tumor cell proliferation. Oncogene 2004;23:9247-58.
38. Kojima F, Naraba H, Sasaki Y, Beppu M, Aoki H, Kawai S. Prostaglandin E2 is an enhancer of interleukin-1beta-induced expression of membrane-associated prostaglandin E synthase in rheumatoid synovial fibroblasts. Arthritis Rheum 2003; 48:2819-28.
39. Faour WH, He Y, He OW et al. Prostaglandin E(2) regulates the level and stability of cyclooxygenase-2 mRNA through activation of p38 mitogen-activated protein kinase in interleukin-1 beta-treated human synovial fibroblasts. J Biol Chem 2001; 276:31720-31.
40. Billinghurst RC, Dahlberg L, Ionescu M et al. Enhanced cleavage of type II collagen by collagenases in osteoarthritic articular cartilage. J Clin Invest 1997;99:1534-45.
41. Legendre F, Bogdanowicz P, Martin G et al. Rhein, a diacerhein-derived metabolite, modulates the expression of matrix degrading enzymes and the cell proliferation of articular chondrocytes by inhibiting ERK and JNK-AP-1 dependent pathways. Clin Exp Rheumatol 2007;25:546-55.
42. Berenbaum F, Jacques C, Thomas G, Corvol MT, Bereziat G, Masliah J. Synergistic effect of interleukin-1 beta and tumor necrosis factor alpha on PGE2 production by articular chondrocytes, does not involve PLA2 stimulation. Exp Cell Res 1996; 222:379-84.
43. Alvarez-Soda MA, Largo R, Sanchez-Pemaute O, Calvo E, Egido J, Herrero-Beaumont G. Prostaglandin E2 receptors EP1 and EP4 are up-regulated in rabbit chondrocytes by IL-1beta, but not by TNFalpha. Rheumatol Int 2007;27:911-17.
44. He W, Palletier JP, Martel-Pelletier J, Laufer S, Di Battista JA. Synthesis of interleukin 1B, tumor necrosis factor-a, and interstitial collagenase (MMP-1) is eicosanoid dependent in human osteoarthritis synovial membrane explants: Interactions with antinflammatory cytokines. J Rheumatol 2002;29:546-53.
45. Pillinger MH, Rosenthal PB, Tolani SN et al. Cyclooxygenase-2-derived E prostaglandins down-regulate matrix metalloprotainase-1 expression in fibroblast-like synoviocytes via inhibition of extracellular signal-regulated kinase activation. J Immunol 2003;171:6080-9.
46. Huskisson EC, Berry H, Gishen P, Jubb RW, Whitehead J. Effects of antinflammatory drugs on the progression of osteoarthrittis ot the knee. LINK Study Group. Longitudinal Investigation of Nonsteroidal Antiinflammatory Drugs in Knee Osteoarthritis. J Rheumatol 1995;22:1941-6.
47. Mengshol JA, Vincenti MP, Brinckerhoff CE. IL-1 induces collagenase-3 (MMP-13) promoter activity in stably transfected chondrocytic cells: requirement for Runx-2 and activation by p38 MAPK and JNK pathways. Nucleic Acids Res 2001;29:4361-72.
48. Kida Y, Kobayashi M, Suzuki T et al. Interleukin-1 stimulates cytokines, prostaglandin E2 and matrix metalloproteinase-1 production via activation of MAPK/AP-1 and NF-kappaB in human gingival fibroblasts. Cytokine 2005;29:159-68.
49. Guilak F, Fermor B, Keefe FJ et al. The role of biomechanics and inflammation in cartilage injury and repair. Clin Orthop Relat Res 2004;423:17-26.
50. Largo R, Díez-Ortego I, Sanchez-Permaute O, Alvarez-Soria MA, Egido J, Herrero-Beaumont G. EP2/EP4 signalling inhibits monocyte chemoattractant protein-1 production induced by interleukin 1beta in synovial fibroblasts. Ann Rheum Dis 2004;63:1197-204.
51. Takahashi HK, Iwagaki H, Yoshino T et al. Prostagtandin E(2) inhibits IL-18-induced ICAM-1 and B7.2 expression through EP2/EP4 receptors in human peripheral blood mononuclear cells. J Immunol 2002;168:4446-54.